IL1B and type 2 diabetes mellitus: Based on these findings, we evaluated the impact of a broad-action (I-BET151) and a more specifically inflammation-targeting (GSK046)28 bromodomain inhibitor in two models of human β-cell dysfunction in T1D and T2D, respectively the cytokines IFNγ + IL1β that contribute to β-cell apoptosis at more advanced stages of islet inflammation in T1D and the metabolic stressor palmitate that contributes to β-cell dysfunction and death in T2D.10